Story perspectives

Johnson & Johnson Acquires Halda for $3.05 Billion Cancer Push

12/30/2025

Summary

Story summary

Johnson & Johnson (J&J) completed its $3.05 billion acquisition of Halda Therapeutics, a clinical-stage cancer biotech.
The deal adds HLD-0915, an oral therapy for prostate cancer, and other experimental drugs.
J&J executives call the acquisition a strategic milestone for redefining cancer treatment.
The company expects about a $0.20 dilution to adjusted earnings per share for Q4 2025 and 2026.
Investors will receive more details during the January 21, 2026 earnings call.

1 of 1

Story summary

Johnson & Johnson (J&J) completed its $3.05 billion acquisition of Halda Therapeutics, a clinical-stage cancer biotech.
The deal adds HLD-0915, an oral therapy for prostate cancer, and other experimental drugs.
J&J executives call the acquisition a strategic milestone for redefining cancer treatment.
The company expects about a $0.20 dilution to adjusted earnings per share for Q4 2025 and 2026.
Investors will receive more details during the January 21, 2026 earnings call.